Patents Examined by Jehanne S. Sitton
  • Patent number: 12024541
    Abstract: Provided is a method of characterising a polynucleotide using a transmembrane pore, wherein the pore is a double pore comprising a first Csg G pore, or a homologue thereof, and a second CsgG pore, or a homologue thereof.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: July 2, 2024
    Assignees: Oxford Nanopore Technologies PLC, VIB VZW, Vrije Universiteit Brussel
    Inventors: Lakmal Nishantha Jayasinghe, Elizabeth Jayne Wallace, Pratik Raj Singh, Richard George Hambley, Michael Jordan, Han Remaut
  • Patent number: 12006549
    Abstract: Methods involving analysis of pretreatment leukocyte expression profiles for prognostic assessment of seizure outcome following a treatment or medical procedure, such as stereotactic laser amygdalohippocampotomy (SLAH). In one aspect, RNA sequencing (RNA-Seq) on whole blood leukocyte samples is taken from a patient with intractable epilepsy prior to SLAH. Differential expression (DE) analysis revealed 24 significantly dysregulated genes (?2.0-fold change, p-value <0.05, and False Discovery Rate, FDR <0.05) useful in prognostic assessment.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: June 11, 2024
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Martin E. Weinand, Ryan Sprissler, Michael F. Hammer
  • Patent number: 11976328
    Abstract: Disclosed are biomarkers, methods and assay systems for the identification of poor prognosis of interstitial pneumonia (pulmonary fibrosis) in an individual diagnosed with suspected of having interstitial pneumonia.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: May 7, 2024
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: David A. Schwartz, Tasha E. Fingerlin, Weiming Zhang
  • Patent number: 11971411
    Abstract: The present invention provides methods for screening and diagnosing prostate cancer based on a correlation between cancer cell growth, cancer lethality or recurrence and the expression level of ZFP36 or NEDD9 and PTEN in conjunction with ZFP36. The disclosure also provides methods for screening and diagnosing prostate cancer based on a correlation between cancer lethality and the genotype of rs1910301 SNP. Also provided are methods for treating prostate cancer comprising providing a treatment or monitoring based on the expression level of ZFP36, the expression level of NEDD9, and the expression level of ZFP36 in conjunction with PTEN levels or the genotype of rs1910301 SNP.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: April 30, 2024
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Curtis Huttenhower, Travis Gerke, Christopher Sweeney, Lorelei Mucci, Gwo-Sho Mary Lee, Daniela Bornigen, Xiaodong Wang, Svitlana Tyekucheva, Kristina Jordahl
  • Patent number: 11971402
    Abstract: The present invention relates to methods and kits for prognosing, treating, and managing treatment of cancer in a subject. The methods involve selecting a subject having cancer and obtaining, from the selected subject, a sample containing exosomes or an S100 molecule containing sample. The exosomes or S100 molecule containing sample, respectively, are then contacted with one or more reagents suitable to detect higher or lower levels or the presence or absence of one or more integrins on said exosomes or higher or lower levels or the presence or absence of one or more S100 molecules in the S100 molecule containing sample. The cancer is then prognosed, treatment is administered, or treatment is managed.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: April 30, 2024
    Assignee: CORNELL UNIVERSITY
    Inventors: David C. Lyden, Ayuko Hoshino, Bruno Da Silva
  • Patent number: 11957664
    Abstract: Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.
    Type: Grant
    Filed: March 23, 2023
    Date of Patent: April 16, 2024
    Assignee: University of Virginia Patent Foundation
    Inventor: Bankole A. Johnson
  • Patent number: 11946934
    Abstract: The present disclosure relates to a biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof. The present disclosure provides a marker, a composition, and a kit for predicting the sensitivity to a protein kinase inhibitor, and a prediction method thereof. According to the present disclosure, the marker has an excellent effect of predicting the sensitivity to a protein kinase inhibitor, and thus the present disclosure can be useful for cancer treatment.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: April 2, 2024
    Assignee: Wellmarker Bio Co., LTD.
    Inventors: Dong Hoon Jin, Seung Woo Hong, Jai Hee Moon, Jae Sik Shin
  • Patent number: 11913072
    Abstract: Provided herein are methods and compositions to detect MET exon 14 skipping using RT-PCR, and methods of treating individuals with MET exon 14 deleted cancers.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: February 27, 2024
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Cindy Cheung, Grantland Hillman, Xiaoju Max Ma, Chitra Manohar, Lily Wong
  • Patent number: 11913075
    Abstract: The subject matter disclosed herein is generally directed to detecting and modulating novel gene signatures for the treatment and prognosis of cancer. The novel gene signatures predict overall survival in cancer and can be targeted therapeutically.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: February 27, 2024
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, Dana-Farber Cancer Institute, Inc.
    Inventors: Aviv Regev, Orit Rozenblatt-Rosen, Benjamin Izar, Livnat Jerby, Asaf Rotem
  • Patent number: 11884966
    Abstract: Provided herein are compositions comprising tissue-specific markers for identifying a tissue of origin of a cell-free nucleic acid, e.g., a cell-free DNA molecule. Also provided herein are methods, compositions, and systems for identifying a tissue of origin of a cell-free nucleic acid by determining an absolute amount of cell-free nucleic acids comprising the tissue-specific marker. Also provided herein are methods, compositions, and systems for detecting a cancer in a tissue of an organism by analyzing tissue-specific markers.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: January 30, 2024
    Assignee: GRAIL, LLC
    Inventors: Yuk-Ming Dennis Lo, Rossa Wai Kwun Chiu, Kwan Chee Chan, Wanxia Gai, Lu Ji
  • Patent number: 11884979
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: January 30, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • Patent number: 11859250
    Abstract: The present invention relates to methods for identifying an EoE endotype of a patient and treating the patient with one or more therapies targeted to the patient's disease endotype; and related methods for stratifying patients for clinical trials.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: January 2, 2024
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Marc E. Rothenberg, Tetsuo Shoda, Ting Wen
  • Patent number: 11840731
    Abstract: Methods and products for identifying individuals who are likely to respond in a positive (benefit) or negative (harm) manner to a pharmacological drug treatment intended for treating or preventing a neuropsychiatric disorder, neurodegeneration, sleep-wake cycles such including and not limited to Alzheimer's disease, schizophrenia, autism and attention disorders based on single nucleotide polymorphisms (SNP) chromosome 2, 2:107,510,000-107,540,000 locus (as disclosed in the Genome Reference Consortium Human genome build 37 (GRCh37)).
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: December 12, 2023
    Assignee: NEURIM PHARMACEUTICALS (1991) LTD.
    Inventors: Nava Zisapel, Moshe Laudon
  • Patent number: 11834700
    Abstract: According to one embodiment, a method includes dispensing the specimen into first1 to firstn containers configured to capture the target particle, removing a contaminant other than the target particle to be captured from the specimen, adding first to m-th probes to the first1 to firstn containers, removing excessive first to m-th probes that have not bound to the target particle, individually amplifying the reporter portion for each of the first1 to firstn containers using the common primer set to obtain first to n-th amplification products, removing an excessive common primer set from the first to n-th amplification products, dispensing the first to n-th amplification products into second1 to secondm containers respectively, amplifying the amplification products in the second1 to secondm containers using the first to m-th specific primer sets, and analyzing presence or absence or types of the target particles captured in the first1 to firstn containers.
    Type: Grant
    Filed: September 13, 2021
    Date of Patent: December 5, 2023
    Assignee: Kabushiki Kaisha Toshiba
    Inventor: Yoshiaki Sugizaki
  • Patent number: 11834723
    Abstract: The present disclosure is directed to improved methods and compositions for the detection of enterovirus D68.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: December 5, 2023
    Assignee: Washington University
    Inventors: Gregory A Storch, Todd N. Wylie, Kristine M. Wylie
  • Patent number: 11821041
    Abstract: The invention is a method of predicting recurrence of colorectal cancer in a patient following surgery, the method comprising analysis of circulating tumor DNA from a patient's sample.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: November 21, 2023
    Assignee: Roche Sequencing Solutions, Inc.
    Inventors: Hans-Peter Adams, Aarthi Balasubramanyam, Bernd Hinzmann, John Lee, John Palma, Andre Rosenthal, Urich-Peter Rohr
  • Patent number: 11814683
    Abstract: Some embodiments are directed to a prognostic method for determining whether a subject is at risk of having the CLAD, comprising: measuring the expression level of POU2AF1 or BLK in a biological sample obtained from the subject; comparing the expression level of POU2AF1 or BLK with a predetermined reference value and concluding that the subject is at risk of having CLAD when the expression level of POU2AF1 or BLK is lower than the predetermined reference value.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: November 14, 2023
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique, Université de Nantes, Centre Hospitalier Universitaire de Nantes
    Inventors: Pierre-Joseph Royer, Antoine Magnan, Sophie Brouard, Richard Danger
  • Patent number: 11807907
    Abstract: Methods and products for identifying individuals who are likely to respond in a positive (benefit) or negative (harm) manner to a pharmacological drug treatment intended for treating or preventing a neuropsychiatric disorder, neurodegeneration, sleep-wake cycles such including and not limited to Alzheimer's disease, schizophrenia, autism and attention deficit disorders based on single nucleotide polymorphisms (SNP) chromosome 2, 2:107,510,000-107,540,000 locus (as disclosed in the Genome Reference Consortium Human genome build 37 (GRCh37)).
    Type: Grant
    Filed: July 28, 2022
    Date of Patent: November 7, 2023
    Assignee: NEURIM PHARMACEUTICALS (1991) LTD.
    Inventors: Nava Zisapel, Moshe Laudon
  • Patent number: 11807906
    Abstract: The present disclosure provides methods for assessing likelihood of development of HIV-associated neurocognitive disorder (HAND) in a HIV patient. Also provided herein are methods for treating a HIV patient, such as, a HIV patient with increased level of a mi RNA that downregulates a peroxin and/or decreased level of a peroxisomal activity biomarker and/or increased level of a substrate of a peroxisomal enzyme. The present disclosure also provides methods for monitoring efficacy of a treatment regimen for a HIV patient.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: November 7, 2023
    Inventors: Tom C. Hobman, Chris Power, Zaikun Xu
  • Patent number: 11788145
    Abstract: The finding that multiple cancers lack one of two NMTs, while stromal and normal tissues do not, enables the treatment of NMT2-deficient cancer cells with an NMT inhibitor. It is shown herein that NMT2 expression is reduced or eliminated in certain cancers, and in one example lymphomas, via an epigenetic mechanism(s). Reduction or elimination of NMT2 expression renders the cancer sensitive inhibitors of NMT.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: October 17, 2023
    Assignee: PACYLEX PHARMACEUTICALS INC.
    Inventors: Luc G. Berthiaume, Erwan Beauchamp